Vito Lorusso

5.2k total citations · 1 hit paper
135 papers, 3.2k citations indexed

About

Vito Lorusso is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Vito Lorusso has authored 135 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 91 papers in Oncology, 35 papers in Pulmonary and Respiratory Medicine and 30 papers in Cancer Research. Recurrent topics in Vito Lorusso's work include Cancer Treatment and Pharmacology (54 papers), Colorectal Cancer Treatments and Studies (31 papers) and Breast Cancer Treatment Studies (22 papers). Vito Lorusso is often cited by papers focused on Cancer Treatment and Pharmacology (54 papers), Colorectal Cancer Treatments and Studies (31 papers) and Breast Cancer Treatment Studies (22 papers). Vito Lorusso collaborates with scholars based in Italy, United States and Switzerland. Vito Lorusso's co-authors include Nicola Silvestris, Agnese Latorre, Alberto Spinazzi, Gianpaolo Pirovano, Miles A. Kirchin, István Láng, Janja Ocvirk, Eugenio Marcuello, Derek J. Jonker and Stuart Osborne and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Scientific Reports.

In The Last Decade

Vito Lorusso

130 papers receiving 3.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial

2013 438 citations Vito Lorusso et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Vito Lorusso Italy	29	1.6k	735	648	588	505	135	3.2k
Andrew Lake United States	7	1.5k 0.9×	736 1.0×	782 1.2×	768 1.3×	225 0.4×	15	3.3k
Vito Lorusso Italy	33	1.6k 1.0×	389 0.5×	1.4k 2.2×	769 1.3×	609 1.2×	162	4.0k
Ganessan Kichenadasse Australia	30	1.9k 1.1×	385 0.5×	1.1k 1.7×	612 1.0×	201 0.4×	168	3.4k
René Bruno France	35	2.8k 1.7×	700 1.0×	1.0k 1.6×	913 1.6×	668 1.3×	128	4.7k
Christos Markopoulos Greece	33	2.5k 1.5×	1.7k 2.3×	615 0.9×	1.0k 1.7×	366 0.7×	198	4.7k
Enzo Galligioni Italy	30	1.7k 1.1×	720 1.0×	1.2k 1.8×	1.1k 1.8×	365 0.7×	166	3.5k
Ondřej Topolčan Czechia	31	1.6k 0.9×	1.1k 1.5×	1.0k 1.6×	1.3k 2.2×	278 0.6×	254	4.2k
Paul G. Kluetz United States	34	1.8k 1.1×	608 0.8×	1.3k 1.9×	579 1.0×	565 1.1×	174	4.0k
Gina G. Chung United States	25	1.5k 0.9×	911 1.2×	510 0.8×	1.3k 2.3×	304 0.6×	68	3.2k
S. Kyriakides Italy	8	2.1k 1.3×	2.0k 2.7×	795 1.2×	526 0.9×	627 1.2×	13	3.6k

Countries citing papers authored by Vito Lorusso

Since Specialization

Citations

This map shows the geographic impact of Vito Lorusso's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vito Lorusso with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vito Lorusso more than expected).

Fields of papers citing papers by Vito Lorusso

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vito Lorusso. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vito Lorusso. The network helps show where Vito Lorusso may publish in the future.

Co-authorship network of co-authors of Vito Lorusso

This figure shows the co-authorship network connecting the top 25 collaborators of Vito Lorusso. A scholar is included among the top collaborators of Vito Lorusso based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vito Lorusso. Vito Lorusso is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Comes, Maria Colomba, Annarita Fanizzi, Samantha Bove, et al.. (2024). Explainable 3D CNN based on baseline breast DCE-MRI to give an early prediction of pathological complete response to neoadjuvant chemotherapy. Computers in Biology and Medicine. 172. 108132–108132. 8 indexed citations

Fanizzi, Annarita, Domenico Pomarico, Alessandro Rizzo, et al.. (2023). Machine learning survival models trained on clinical data to identify high risk patients with hormone responsive HER2 negative breast cancer. Scientific Reports. 13(1). 8575–8575. 5 indexed citations

Cuomo, Arturo, Marco Cascella, Cira Antonietta Forte, et al.. (2020). Careful Breakthrough Cancer Pain Treatment through Rapid-Onset Transmucosal Fentanyl Improves the Quality of Life in Cancer Patients: Results from the BEST Multicenter Study. Journal of Clinical Medicine. 9(4). 1003–1003. 34 indexed citations

Lorusso, Vito. (2016). Management of chemotherapy-induced nausea and vomiting by risk profile: role of netupitant/palonosetron. Therapeutics and Clinical Risk Management. 12. 917–917. 19 indexed citations

Gnoni, Antonio, Daniele Santini, Mario Scartozzi, et al.. (2015). Hepatocellular carcinoma treatment over sorafenib: epigenetics, microRNAs and microenvironment. Is there a light at the end of the tunnel?. Expert Opinion on Therapeutic Targets. 19(12). 1623–1635. 56 indexed citations

Silvestris, Nicola, Ilaria Marech, Anna Elisabetta Brunetti, et al.. (2014). Predictive factors to targeted treatment in gastrointestinal carcinomas. Cancer Biomarkers. 14(2-3). 151–162. 3 indexed citations

Aapro, Matti, H. S. Rugo, Antônio Rossi, et al.. (2014). A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. Annals of Oncology. 25(7). 1328–1333. 180 indexed citations

Strippoli, Sabino, et al.. (2013). Herbal-drug interaction induced rhabdomyolysis in a liposarcoma patient receiving trabectedin. BMC Complementary and Alternative Medicine. 13(1). 199–199. 23 indexed citations

Lorusso, Vito. (2012). Which role for EGFR therapy in breast cancer. Frontiers in Bioscience-Scholar. S4(1). 31–42. 4 indexed citations

10.

Lorusso, Vito, et al.. (2011). Vacuum-assisted biopsy diagnosis of atypical ductal hyperplasia and patient management. La radiologia medica. 116(2). 276–291. 22 indexed citations

11.

Santoro, Armando, Alessandro Comandone, Lorenza Rimassa, et al.. (2008). A phase II randomized multicenter trial of gefitinib plus FOLFIRI and FOLFIRI alone in patients with metastatic colorectal cancer. Annals of Oncology. 19(11). 1888–1893. 42 indexed citations

12.

Ramponi, Simona, Claudia Cabella, Stefania Vultaggio, et al.. (2008). Contrast‐enhanced MRI of murine sponge model for progressive angiogenesis assessed with gadoteridol (ProHance) and gadocoletic acid trisodium salt (B22956/1). Journal of Magnetic Resonance Imaging. 27(4). 872–880. 4 indexed citations

13.

Palmeri, S., Vito Lorusso, Laura Palmeri, et al.. (2006). Cisplatin and gemcitabine with either vinorelbine or paclitaxel in the treatment of carcinomas of unknown primary site. Cancer. 107(12). 2898–2905. 34 indexed citations

14.

Berruti, Alfredo, Raffaella Bitossi, G. Gorzegno, et al.. (2005). Paclitaxel, vinorelbine and 5-fluorouracil in breast cancer patients pretreated with adjuvant anthracyclines. British Journal of Cancer. 92(4). 634–638. 8 indexed citations

15.

Frasci, G., Vito Lorusso, Nicola Panza, et al.. (2001). Gemcitabine plus vinorelbine yields better survival outcome than vinorelbine alone in elderly patients with advanced non-small cell lung cancer. A Southern Italy Cooperative Oncology Group (SICOG) phase III trial. Lung Cancer. 34. 65–69. 66 indexed citations

16.

Donadio, Michela, Alfredo Berruti, Alberto Bottini, et al.. (2001). Paclitaxel administration on days 1 and 8 every 21 days in anthracycline-pretreated metastatic breast cancer patients. A multicenter phase II trial. Cancer Chemotherapy and Pharmacology. 47(5). 391–396. 8 indexed citations

17.

Comella, Pasquale, Nicola Panza, Luigi Manzione, et al.. (2000). Interim Analysis of a Phase III Trial Comparing Cisplatin, Gemcitabine, and Vinorelbine vs. Either Cisplatin and Gemcitabine or Cisplatin and Vinorelbine in Advanced Non–Small-Cell Lung Cancer. A Southern Italy Cooperative Oncology Group Study. Clinical Lung Cancer. 1(3). 202–207. 7 indexed citations

18.

Spinazzi, Alberto, Vito Lorusso, Gianpaolo Pirovano, & Miles A. Kirchin. (1999). Safety, tolerance, biodistribution, and MR imaging enhancement of the liver with gadobenate dimeglumine: Results of clinical pharmacologic and pilot imaging studies in nonpatient and patient volunteers. Academic Radiology. 6(5). 282–291. 168 indexed citations

19.

Lena, M. De, Vito Lorusso, Mario Brandi, et al.. (1997). Revertant and potentiating activity of lonidamine in patients with ovarian cancer previously treated with platinum.. Journal of Clinical Oncology. 15(10). 3208–3213. 28 indexed citations

20.

Coviello, M., et al.. (1992). Determination of intraperitoneal mitoxantrone in the serum of cancer patients using a high performance liquid chromatograph coupled to an advanced automated sample processor (AASP)®. Biomedical Chromatography. 6(4). 168–171. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact